Income Taxes	9 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE L – INCOME TAXES Income tax expense for the three and nine months ended December 31, 2016 was approximately $84 million and $257 million, respectively, compared with income tax expense for the three and nine months ended December 31, 2015 of approximately $59 million and $222 million, respectively. For the three and nine months ended December 31, 2015, the Company recognized a net discrete tax benefit of approximately $19 million and $16 million, respectively, resulting primarily from the resolution of uncertain tax positions for non-U.S. jurisdictions, refinements of tax positions taken in prior periods and the retroactive reinstatement in December 2015 of the research and development tax credit in the U.S. The Company’s estimated annual effective tax rate, which excludes the impact of discrete items, for the nine months ended December 31, 2016 and 2015 was 28.9% and 29.0%, respectively. Changes in tax laws, the outcome of tax audits and any other changes in potential tax liabilities may result in additional tax expense or benefit in fiscal year 2017, which are not considered in the Company’s estimated annual effective tax rate. While the Company does not currently view any such items as individually material to the results of the Company’s consolidated financial position or results of operations, the impact of certain items may yield additional tax expense or benefit in the remaining quarter of fiscal year 2017. The Company is anticipating a fiscal year 2017 effective tax rate between 28% and 29%.

Income Taxes

9 Months Ended

Dec. 31, 2016

NOTE L – INCOME TAXES

Income tax expense for the three and nine months ended December 31, 2016 was approximately $84 million and $257 million, respectively, compared with income tax expense for the three and nine months ended December 31, 2015 of approximately $59 million and $222 million, respectively. For the three and nine months ended December 31, 2015, the Company recognized a net discrete tax benefit of approximately $19 million and $16 million, respectively, resulting primarily from the resolution of uncertain tax positions for non-U.S. jurisdictions, refinements of tax positions taken in prior periods and the retroactive reinstatement in December 2015 of the research and development tax credit in the U.S.

The Company’s estimated annual effective tax rate, which excludes the impact of discrete items, for the nine months ended December 31, 2016 and 2015 was 28.9% and 29.0%, respectively. Changes in tax laws, the outcome of tax audits and any other changes in potential tax liabilities may result in additional tax expense or benefit in fiscal year 2017, which are not considered in the Company’s estimated annual effective tax rate. While the Company does not currently view any such items as individually material to the results of the Company’s consolidated financial position or results of operations, the impact of certain items may yield additional tax expense or benefit in the remaining quarter of fiscal year 2017. The Company is anticipating a fiscal year 2017 effective tax rate between 28% and 29%.